AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17973945 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day)
Number of subjects: 72
Study 17973945 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (40 mg/day)
Number of subjects: 72
Study 17973945 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of ezetimibe and simvastatin
Number of subjects: 72
Study 16025262 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine 740 mg/m2
Number of subjects: 71
Study 16025262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 12681863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 34
Study 10493846 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient group-training programme (n=50)
Number of subjects: 101
Study 10493846 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=51)
Number of subjects: 101
Study 9092413 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 (ReoPro)
Number of subjects: 0
Study 9092413 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inhibitors (integrelin, lamifiban, tirofiban)
Number of subjects: 0
Study 1788581 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 0
Study 1788581 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 0
Study 1788581 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.25 mg
Number of subjects: 0
Study 1788581 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0
Study 1788581 — intervention group
Group type: COMPARATOR
Intervention: No anti-emetic prophylaxis
Number of subjects: 0
Study 6119998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.011 mg kg‐1)
Number of subjects: 29
Study 6119998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.010 mg kg‐1)
Number of subjects: 29
Study 6119998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 29
Study 31950307 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived partner support of PrEP use
Number of subjects: 659
Study 31950307 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefit of PrEP use
Number of subjects: 659
Study 31950307 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived partner support of PrEP and benefit of PrEP use
Number of subjects: 659
Study 30897393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stigma assessment
Number of subjects: 80
Study 29176675 — intervention group
Group type: EXPERIMENTAL
Intervention: High-probability condition
Number of subjects: 0
Study 29176675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-probability condition
Number of subjects: 0
Study 25662503 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm pen needle (PN)
Number of subjects: 274
Study 24571205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-daily
Number of subjects: 610
Study 24571205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 22489544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative play in Halo II
Number of subjects: 0
Study 22489544 — intervention group
Group type: COMPARATOR
Intervention: Competitive play in Halo II
Number of subjects: 0
Study 19686113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% (w/w) monosodium L-glutamate (MSG) added to rice gruel, 3 times a day for 3 months
Number of subjects: 29
Study 19686113 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 29
Study 19686113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% (w/w) monosodium L-glutamate (MSG)
Number of subjects: 29
Study 17890515 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of exposure
Number of subjects: 34
Study 17890515 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of exposure coupled with informative context
Number of subjects: 34
Study 17890515 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary lessons
Number of subjects: 34
Study 15077088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 20
Study 15077088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12148249 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Peroxyborate (CHX + PER)
Number of subjects: 28
Study 12148249 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine alone (CHX)
Number of subjects: 28
Study 9794022 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 210
Study 9794022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behaviour therapy
Number of subjects: 210
Study 9794022 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help
Number of subjects: 210
Study 9794022 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study 7895928 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (8 mg/h after a bolus of 80 mg)
Number of subjects: 10
Study 7895928 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (4 mg/h after a bolus of 80 mg)
Number of subjects: 10
Study 7895928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (0.25 mg/kg/h after a bolus of 50 mg)
Number of subjects: 10
Study 2142869 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 11
Study 322836 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 322836 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 31582549 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 192
Study 31582549 — intervention group
Group type: COMPARATOR
Intervention: No Granulocyte colony-stimulating factor (non-G-CSF)
Number of subjects: 192
Study 31434781 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (laminectomy)
Number of subjects: 150
Study 31434781 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment (structured physical training programme)
Number of subjects: 150
Study 28084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (PRT) program, 3 times a week for 50 weeks (20 weeks supervised, 30 weeks home-based)
Number of subjects: 6
Study 28084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 6
Study 28084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise
Number of subjects: 6
Study 28084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (PRT) program
Number of subjects: 6
Study 28084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 50 weeks
Number of subjects: 6
Study 25773449 — intervention group
Group type: EXPERIMENTAL
Intervention: One Shape (rotary file system)
Number of subjects: 624
Study 25773449 — intervention group
Group type: COMPARATOR
Intervention: Reciproc (reciprocating file system)
Number of subjects: 624
Study 23220856 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil dosage adjusted according to SPI
Number of subjects: 170
Study 23220856 — intervention group
Group type: COMPARATOR
Intervention: Clinical parameters (Control)
Number of subjects: 170
Study 21669894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose plus EMLA cream (S+E group)
Number of subjects: 76
Study 21669894 — intervention group
Group type: COMPARATOR
Intervention: Sucrose plus placebo cream (S group)
Number of subjects: 76
Study 19368751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and familial factors
Number of subjects: 439
Study 19368751 — intervention group
Group type: EXPERIMENTAL
Intervention: View of self, view of the world, internal attributional style, need for social approval, positive problem-solving orientation, and family problems
Number of subjects: 439
Study 16959024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) treatment
Number of subjects: 12
Study 16959024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 12
Study 16959024 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 15074090 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus Zhuanyindan (ICWM group)
Number of subjects: 82
Study 15074090 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuanyindan (TCM group)
Number of subjects: 82
Study 15074090 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (WM group)
Number of subjects: 82
Study 11526360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce treadmill protocol
Number of subjects: 15
Study 11526360 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Naughton treadmill protocol
Number of subjects: 15
Study 11526360 — intervention group
Group type: COMPARATOR
Intervention: Bicycle testing
Number of subjects: 15
Study 11526360 — intervention group
Group type: COMPARATOR
Intervention: Modified Naughton protocol
Number of subjects: 15
Study 11526360 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce protocol (retrospective analysis)
Number of subjects: 15
Study 9357385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 micrograms
Number of subjects: 550
Study 9357385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms
Number of subjects: 550
Study 9357385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 8253929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN)
Number of subjects: 120
Study 8253929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8253929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GTN and placebo
Number of subjects: 120
Study 3956275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-antagonist)
Number of subjects: 15
Study 3956275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31490861 — intervention group
Group type: EXPERIMENTAL
Intervention: Early self-directed home exercise program (HEP) for 6 weeks with weekly supportive telephone calls
Number of subjects: 30
Study 31490861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 29717497 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping/neutral condition
Number of subjects: 0
Study 29717497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindering/neutral condition
Number of subjects: 0
Study 29717497 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice task
Number of subjects: 0
Study 29717497 — intervention group
Group type: COMPARATOR
Intervention: Neutral agent
Number of subjects: 0
Study 29717497 — intervention group
Group type: COMPARATOR
Intervention: Hinderer
Number of subjects: 0
Study 27684290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg oral dose
Number of subjects: 157
Study 27684290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole treatment
Number of subjects: 157
Study 27684290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole concentrations
Number of subjects: 157
Study 27684290 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC
Number of subjects: 157
Study 24515927 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games (n = 15)
Number of subjects: 29
Study 24515927 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (n = 14)
Number of subjects: 29
Study 22252780 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 117
Study 20335281 — intervention group
Group type: EXPERIMENTAL
Intervention: FTCQ-12
Number of subjects: 310
Study 18314230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacylglycerol oil (25 g/day for 120 days)
Number of subjects: 127
Study 18314230 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol oil (25 g/day for 120 days)
Number of subjects: 127
Study 15780649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge with subtalar strapping for less than 5 hours daily (short group), n=21
Number of subjects: 81
Study 15780649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge with subtalar strapping for 5-10 hours daily (medium group), n=20
Number of subjects: 81
Study 15780649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge with subtalar strapping for greater than 10 hours daily (long group), n=18
Number of subjects: 81
Study 15780649 — intervention group
Group type: COMPARATOR
Intervention: Subtalar strapping band without lateral wedge (placebo group), n=22
Number of subjects: 81
Study 12098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg twice a day)
Number of subjects: 62
Study 12098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 62
Study 12098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg twice a day)
Number of subjects: 62
Study 12098171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 62
Study 12098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 62
Study 10335002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64) attended three education sessions, each of 90 minutes duration, spread over three successive weeks.
Number of subjects: 125
Study 10335002 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 61) received usual care.
Number of subjects: 125
Study 10335002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64) after three education sessions.
Number of subjects: 125
Study 10335002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64)
Number of subjects: 125
Study 8632365 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared tympanic thermometer (ITT)
Number of subjects: 4
Study 2103687 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 80
Study 2103687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7443923 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Ratio (VR) feedback schedule
Number of subjects: 36
Study 7443923 — intervention group
Group type: COMPARATOR
Intervention: Continuous feedback
Number of subjects: 36
Study 7443923 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 36
Study 6357892 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate cream 0.05%
Number of subjects: 40
Study 6357892 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone butyrate cream 0.1%
Number of subjects: 40
Study 31345717 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking in the ME4C
Number of subjects: 25
Study 29095407 — intervention group
Group type: COMPARATOR
Intervention: Non-SAE group
Number of subjects: 105
Study 29095407 — intervention group
Group type: EXPERIMENTAL
Intervention: SAE group
Number of subjects: 105
Study 27113290 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (PCT, 2 μg/day)
Number of subjects: 88
Study 27113290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 24704050 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 group
Number of subjects: 35
Study 24704050 — intervention group
Group type: COMPARATOR
Intervention: ICM group
Number of subjects: 35
Study 21848948 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90mg
Number of subjects: 222
Study 21848948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 20571804 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 kVp and 1.8 ml/kg contrast agent (300 mgI/ml)
Number of subjects: 80
Study 20571804 — intervention group
Group type: COMPARATOR
Intervention: 80 kVp and 1.2 ml/kg contrast agent
Number of subjects: 80
Study 18056526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose
Number of subjects: 201
Study 18056526 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 201
Study 18056526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/d maintenance dose
Number of subjects: 201
Study 18056526 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d maintenance dose
Number of subjects: 201
Study 16096437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day; n=172)
Number of subjects: 340
Study 16096437 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (n=168)
Number of subjects: 340
Study 16096437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 340
Study 16096437 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 340
Study 12404032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg/day
Number of subjects: 14
Study 12404032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg/day
Number of subjects: 14
Study 12404032 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 14
Study 10211917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 31
Study 10211917 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 31
Study 10211917 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 31
Study 10211917 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 31
Study 7596218 — intervention group
Group type: EXPERIMENTAL
Intervention: Epalrestat (aldose reductase inhibitor), treated for one month
Number of subjects: 3
Study 7596218 — intervention group
Group type: COMPARATOR
Intervention: Untreated diabetic patients
Number of subjects: 3
Study 2164706 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine rotavirus vaccine RIT 4237
Number of subjects: 489
Study 2164706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 573246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group (16 subjects)
Number of subjects: 32
Study 573246 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 subjects)
Number of subjects: 32
Study 31811463 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosan therapy (4-min sessions, twice/week for 28 days)
Number of subjects: 39
Study 31811463 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosan therapy
Number of subjects: 39
Study 31811463 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 39
Study 31154088 — intervention group
Group type: EXPERIMENTAL
Intervention: WRN-PPNet (automatic segmentation method)
Number of subjects: 0
Study 31154088 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art methods (control group)
Number of subjects: 0
Study 28990439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fennel (n=30)
Number of subjects: 60
Study 28990439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study 25675199 — intervention group
Group type: COMPARATOR
Intervention: Lowest homoarginine quartile (<1.40 μmol/L)
Number of subjects: 829
Study 25629691 — intervention group
Group type: EXPERIMENTAL
Intervention: IC and high tissue loading
Number of subjects: 6
Study 25629691 — intervention group
Group type: EXPERIMENTAL
Intervention: IC and medium tissue loading
Number of subjects: 6
Study 25629691 — intervention group
Group type: EXPERIMENTAL
Intervention: IC and low tissue loading
Number of subjects: 6
Study 25629691 — intervention group
Group type: EXPERIMENTAL
Intervention: No IC and high tissue loading
Number of subjects: 6
Study 25629691 — intervention group
Group type: EXPERIMENTAL
Intervention: No IC and medium tissue loading
Number of subjects: 6
Study 25629691 — intervention group
Group type: EXPERIMENTAL
Intervention: No IC and low tissue loading
Number of subjects: 6
Study 23217651 — intervention group
Group type: EXPERIMENTAL
Intervention: Care by an emergency nurse practitioner (ENP)
Number of subjects: 320
Study 23217651 — intervention group
Group type: COMPARATOR
Intervention: Care by a doctor (DR)
Number of subjects: 320
Study 23217651 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up health status using Short Form 12
Number of subjects: 320
Study 23217651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse event rate (missed fractures or unplanned representations)
Number of subjects: 320
Study 19770473 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 1294
Study 19770473 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 150 mg
Number of subjects: 1294
Study 19770473 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 50 mg
Number of subjects: 1294
Study 19770473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1294
Study 18074473 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (slow movements of Mozart's piano sonatas)
Number of subjects: 10
Study 18074473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 10
Study 15274426 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (25 mg)
Number of subjects: 137
Study 15274426 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (50 mg)
Number of subjects: 137
Study 15274426 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (75 mg)
Number of subjects: 137
Study 15274426 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (100 mg)
Number of subjects: 137
Study 15274426 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (40 mg)
Number of subjects: 137
Study 15274426 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 137
Study 11298311 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire fixation
Number of subjects: 97
Study 11298311 — intervention group
Group type: COMPARATOR
Intervention: Rigid fixation
Number of subjects: 97
Study 9272794 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning trials with verbal information to impede placebo expectancies
Number of subjects: 0
Study 9272794 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning trials
Number of subjects: 0
Study 9272794 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 0